Cover Image
市場調查報告書

躁鬱症:現在、未來市場參與企業

Bipolar Disorder - Current and Future Players

出版商 GlobalData 商品編碼 365834
出版日期 內容資訊 英文 105 Pages
訂單完成後即時交付
價格
Back to Top
躁鬱症:現在、未來市場參與企業 Bipolar Disorder - Current and Future Players
出版日期: 2016年03月01日 內容資訊: 英文 105 Pages
簡介

本報告提供全球躁鬱症的治療藥市場上現有/新加入企業相關分析,整體市場的未來展望和促進、阻礙因素,現在調查、未來的競爭趨勢,主要企業簡介(企業概要,企業發展,財務狀況,SWOT分析)等。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 市場預測

  • 全球市場
    • 市場預測
    • 促進、阻礙因素:全球市場課題

第4章 現在、未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • 大塚製藥
    • AstraZeneca
    • Eli Lilly
    • Allergan
    • 大日本住友製藥
    • Janssen
    • Lundbeck
    • Meiji Seika Pharma

第5章 附錄

圖表一覽

目錄
Product Code: GDHC1043FPR

GlobalData has released its pharma report, "Bipolar Disorder - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Bipolar Disorder Market. The report identifies and analyses the key companies shaping and driving the global Bipolar Disorder market. The report provides insight into the competitive Bipolar Disorder landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Bipolar Disorder
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Bipolar Disorder sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Bipolar Disorder market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Bipolar Disorder market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers. Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Otsuka
    • 4.3.2. AstraZeneca
    • 4.3.3. Eli Lilly
    • 4.3.4. Allergan
    • 4.3.5. Dainippon Sumitomo
    • 4.3.6. Janssen
    • 4.3.7. Lundbeck
    • 4.3.8. Meiji Seika

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed Bipolar Disorder Patients
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. Launch and Patent Expiry Dates
    • 5.4.4. General Pricing Assumptions
    • 5.4.5. Individual Drug Assumptions
    • 5.4.6. Generic Erosion
  • 5.5. Primary Research. KOLs Interviewed for this Report
  • 5.6. Primary Research. Prescriber Survey
  • 5.7. About the Authors
    • 5.7.1. Analyst
    • 5.7.2. Therapy Area Director
    • 5.7.3. Epidemiologist
    • 5.7.4. Global Director of Therapy Research and Analysis
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecast ($m) for Bipolar Disorder, 2014-2024
  • Table 2: Bipolar Disorder Market - Drivers and Barriers, 2014-2024
  • Table 3: Key Companies in the Bipolar Disorder Market in the 8MM, 2015
  • Table 4: Otsuka's Bipolar Disorder Portfolio Assessment, 2015
  • Table 5: AstraZeneca's Bipolar Disorder Portfolio Assessment, 2015
  • Table 6: Eli Lilly's Bipolar Disorder Portfolio Assessment, 2015
  • Table 7: Allergan's Bipolar Disorder Portfolio Assessment, 2015
  • Table 8: Dainippon Sumitomo's Bipolar Disorder Portfolio Assessment, 2015
  • Table 9: Janssen Bipolar Disorder Portfolio Assessment, 2015
  • Table 10: Lundbeck Bipolar Disorder Portfolio Assessment, 2015
  • Table 11: Meiji Seika Bipolar Disorder Portfolio Assessment, 2015
  • Table 12: Key Launch Dates
  • Table 13: Key Patent Expiries
  • Table 14: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Bipolar Disorder by Region, 2014-2024
  • Figure 2: Global Sales for Bipolar Disorder by Drug Class, 2014-2024
  • Figure 3: Global Sales of Products for Bipolar Disorder by Company, 2014-2024
  • Figure 4: Company Portfolio Gap Analysis in Bipolar Disorder, 2014-2024
  • Figure 5: Otsuka SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 6: AstraZeneca SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 7: Eli Lilly SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 8: Allergan SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 9: Dainippon Sumitomo SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 10: Janssen SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 11: Lundbeck SWOT Analysis in Bipolar Disorder, 2014-2024
  • Figure 12: Meiji Seika SWOT Analysis in Bipolar Disorder, 2014-2024
Back to Top